Trial Profile
A Label Extension, Single Arm Multicentric Phase III Study to Assess the Efficacy and Safety of Stempeucel (Adult Human Bone Marrow Derived, Cultured, Pooled, Allogeneic Mesenchymal Stromal Cells) in Patients with Critical Limb Ischemia Due to Atherosclerotic Peripheral Arterial Disease
Status:
Not yet recruiting
Phase of Trial:
Phase III
Latest Information Update: 04 Jul 2019
Price :
$35
*
At a glance
- Drugs Mesenchymal stem cell therapy (Primary)
- Indications Chronic limb-threatening ischemia; Peripheral ischaemia
- Focus Therapeutic Use
- Sponsors Stempeutics
- 13 Nov 2018 New trial record